

SOCIETY STATEMENT

US FDA Safety Communication on Breast Implant Associated Squamous Cell Carcinoma BIA-SCC)

Mark L. Jewell^{1,2,3} · Jennifer L. Walden^{3,4,5,6} · Montserrat Fontbona^{3,7,8,9} · Lina Triana¹⁰

© Springer Science+Business Media, LLC, part of Springer Nature and International Society of Aesthetic Plastic Surgery 2023

The US Food and Drug Administration (FDA) recently posted a Safety Communication informing healthcare practitioners and patients about reports of squamous cell carcinoma (SCC) and various lymphomas (not including BIA-ALCL) detected in the capsule surrounding breast implants. These reports highlight a very rare occurrence of a malignancy. We believe that developments such as this deserve attention so that you, your staff, and your patients may stay informed.

There have been literature reports of SCC and various lymphomas in the capsule around the breast implants for both textured and smooth breast implants and for both saline and silicone breast implants. The cases were reported in patients who were diagnosed 15–42 years after having breast implants placed, and have all presented with abnormal signs and symptoms including swelling, pain, lumps, or skin changes. Awareness by breast implant

patients and physicians is paramount, as well as emphasis on the need for long-term patient follow-up with their plastic surgeon.

1. The FDA Safety Communication is not new information, nor is it unique to breast implants. Multiple reports of rare malignancies have been reported around several types of implanted medical devices including orthopedic implants, dental implants, pacemakers, and breast implants. The incidence of these malignancies including BIA-SCC is very rare. BIA-SCC, according to the case reports, behaves similarly to BIA-ALCL with local capsular growth followed by systemic metastasis. Primary SCC of the breast (implant-naive patients) is a known rare breast malignancy and is a separate diagnostic entity.
2. Awareness for physicians, their staff, and patients is key. Any abnormalities and deviation from the normal course for breast implant patients should be evaluated by a board-certified plastic surgeon. Plastic surgeons are in the best position to be knowledgeable about breast implants and potential abnormalities that can occur years after implantation.
3. Strongly continue to recommend that breast implant patients have yearly follow-ups and report any changes in their breasts to their surgeon.
4. Breast ultrasound or MRI (approximately 5–6 years postoperatively, then every 2–3 years thereafter) is useful to monitor implant integrity and soft tissues.
5. BIA-SCC treatment recommendations will need to be based on emerging data, and we will continue to update you. There are no established guidelines for treatment.

¹ Plastic Surgery, Oregon Health Science University, Portland, Oregon, USA

² Private Practice, Eugene, Oregon, USA

³ Patient Safety Committee, International Society of Aesthetic Plastic Surgery (ISAPS), Mount Royal, NJ, USA

⁴ The Aesthetic Society (American Society for Aesthetic Plastic Surgery), Garden Grove, USA

⁵ University of Texas Southwestern, Dallas, Texas, USA

⁶ Private Practice, Austin, Texas, USA

⁷ Hospital Militar de Santiago, Santiago, Chile

⁸ Private Practice Clínica Aurea, Santiago, Chile

⁹ Universidad de Los Andes, Bogotá, Colombia

¹⁰ International Society of Aesthetic Plastic Surgery (ISAPS), Mount Royal, NJ, USA

For This Initial Communication, We Recommend The Following Guidelines:

- a. The presentation of BIA-SCC has included a breast/axillary mass, unilateral breast swelling, pain, and/ or erythema.
- b. Surgeons should be aware of BIA-ALCL, BIA-SCC, or other possible breast malignancies when evaluating implant patients for changes in their breasts and should not operate on anyone with a late-forming seroma or capsule mass without an appropriate preoperative work up.
- c. If a seroma is present, the diagnostic tool of choice is an ultrasound, not mammography. The ultrasound-guided fluid aspiration procedure is used to obtain fluid for bacteriological culture and to evaluate for malignancy.
- d. If your patient has a delayed seroma preoperatively, fluid should be sent for cytocentrifuge or cellblock and CD30 testing (BIA-ALCL) to rule out malignancy. Based on this evaluation, the pathologist will be able to decide if any further testing is needed. Most of these cases will have a negative evaluation as late-term seromas are typically non-malignant. Despite this, seromas are typically treated with surgical therapy.
- e. The capsule should be inspected and any suspicious areas submitted for histological evaluation and, when appropriate, immunohistochemical evaluation e.g., keratin, CD5/6, p65 for suspicion of squamous cell carcinoma.
- f. Suspicious abnormalities found in breast implant capsules during routine implant exchange procedures should also be sent for histologic analysis.

ISAPS Patient Safety Committee

References

1. Buchanan PJ, Chopra VK, Walker KL, Rudolph R, Greco RJ (Jul2018) Primary squamous cell carcinoma arising from a breast implant capsule: a case report and review of the literature. *Aesthet Surg J* 38(7):97–102. <https://doi.org/10.1093/asj/sjy092>
2. Adams WP, Culbertson EJ, Deva AP, Magnussun MR, Layt C, Jewell M, Malucci P, Heden P (2017) Macrot textured breast implants with defined steps to minimize bacterial contamination around the device: experience in 42,000 implants. *Plast Reconstr Surg* 140(3):427–431
3. Breast Implants: Reports of Squamous Cell Carcinoma and Various Lymphomas in Capsule Around Implants: FDA Safety Communication. Sep 8, 2022; https://www.fda.gov/medical-devices/safety-communications/breast-implants-reports-squamous-cell-carcinoma-and-various-lymphomas-capsule-around-implants-fda?mkt_tok=MTAxLUJTTy05OTMAAAGGvabdQEZ-XAZ0B6MmGXXr1tXUK6XLU-qIaD_XzFQAbqTBMX01LS9IU-obeX395JdKeCBw_SN-Hi86OW-ViNfpkZgp-2FTaqjTjSRICcb50x-C0d
4. Kitchen SB, Paletta CE, Shehadi SI, Bauer WC (1994) Epithelialization of the lining of a breast implant capsule. Possible origins of squamous cell carcinoma associated with a breast implant capsule. *Cancer* 73(5):1449–1452
5. Liu Z, Liu C, Chenglong Z, Yu Q, Zhang G, Wang X, Yu Z (2021) Breast prosthetic implant-associated squamous cell carcinoma: a case report and literature review. *Res Square*. <https://doi.org/10.21203/rs.3.rs-141167/v1>
6. Paletta C, Paletta FX Jr, Paletta FX Sr 1992 Squamous cell carcinoma following breast augmentation. *Ann Plast Surg*. 29(5):425–429; discussion 429–32
7. Satgunaseelan L, Cheung D, Reddy J (2015) Breast implant-associated squamous cell carcinoma—a rare long term complication. *Pathol* 47(1):72–73
8. Alikhan MB, Nassar A, Mansoor I (2010) Squamous metaplasia on the breast implant capsule. *Int J Surg Pathol*. 18(6):570–574
9. Soni SE, Laun JC, Beard AS, Kuykendall LV (2022) Breast implant capsule-associated squamous cell carcinoma during pregnancy: a mimicker of breast implant-associated anaplastic large cell lymphoma. *Plast Reconstr Surg* 150:926e–928e. <https://doi.org/10.1097/PRS.00000000000009506>
10. Goldberg M et al (2021) Squamous Cell Carcinoma Arising in Breast Implant Capsules. *Ann Plast Surg* 86:268–272
11. Goel P et al (2019) Squamous cell carcinoma following multiple revision breast surgeries with massive chest wall reconstruction via flow-through double ALT free flaps. *Eur J Plast Surg* 42:517–522. <https://doi.org/10.1007/s00238-019-01525-x>
12. Badge S et al (2014) Primary squamous cell carcinoma of the breast. *Int J Appl nd Basic Med Res*. 4(1):120
13. Whaley D et al (2022) Breast implant capsule-associated squamous cell carcinoma: report of two patients. *Int Surg Path*. <https://doi.org/10.1177/10668969221086940>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.